Management of Digestive Haemorrhaging In CHRU of Brest During 2009 and 2014

Gastro Intestinal Bleeding Clinical Trial

— HDréa  

Official title:

Risk Factors for Further Bleeding in Patients Admitted to Intensive Care for Gastro Intestinal Bleeding

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03379285
• Other study ID #: HDréa
• Status: Completed
• Phase: N/A
• First received: November 23, 2017
• Last updated: December 15, 2017
• Start date: October 3, 2016
• Est. completion date: December 31, 2016

Study information

• Verified date: October 2017
• Source: University Hospital, Brest
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Gastro intestinal (GI) bleeding is relatively frequent and may lead to intensive care unit admission. Although a restrictive strategy for red blood cell transfusion is supported by a large randomized controlled trial literature, less is known about the impact of transfusion strategy of other blood components and administration of anti fibrinolytic on clinical outcomes.

This study aims to identify parameters that may be associated with the risk of further bleeding in patients admitted to ICU for GI bleeding.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 272
• Est. completion date: December 31, 2016
• Est. primary completion date: December 31, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with Gastro Intestinal Bleeding admitted to either medical or surgical intensive care unit

Exclusion Criteria:

• patients retrieved from another hospital

• age < 18 years consent withdrawal

Related Conditions & MeSH terms

• Gastro Intestinal Bleeding
• Gastrointestinal Hemorrhage
• Hemorrhage

Locations

Country	Name	City	State
France	CHRU de Brest	Brest

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bleeding	Bleeding persistance or recidive requiring an intervention or a scope	within a week
Secondary	mortality	hospital mortality	during hospitalisation (28 days)